Interleukin-17A Inhibitors in Patients with Psoriasis and Tuberculosis Infection: A 2-Year Prospective Study on Safety Without Preventive Treatment

• DOI: 10.1007/s13555-024-01130-2
• Publication Date: 2024-03-14T14:02:31Z
• Authors: Chun-Xia He; Chao Wu; Li Zhang; Hong-Zhong Jin
• Keywords: 03 medical and health sciences; Interferon-γ release assay; IGRA; 0302 clinical medicine; Prophylaxis; RL1-803; Psoriasis; Dermatology; Safety; Interleukin-17A; Original Research

The necessity for tuberculosis preventive treatment (TPT) and routine T-SPOT.TB monitoring in patients with psoriasis infection (TBI) undergoing interleukin (IL)-17A inhibitor therapy remains uncertain. This study aims to evaluate the long-term safety of IL-17A inhibitors administered without TPT analyze changes among these patients. It also identifies risk factors TBI psoriasis. single-center prospective enrolled adult plaque receiving inhibitors. was defined as positive results (≥ 6 spots) symptoms or evidence active (ATB). administration based on contraindications, factors, patient preferences. primary endpoint incidence ATB over 2 years. Secondary outcomes included factors. Of 129 study, 97 (75.2%) did not receive TPT, while 32 (24.8%) did. Among them, 109 (84.5%) completed 2-year follow-up. During 235 person-years observation, no cases were identified. Median values showed significant from baseline year both non-TPT (20 vs. 17 spots, p = 0.975) groups (55 58 0.830). reversed 14 (12.8%), mostly group. Moreover, factor analysis, a cohort 212 negative evaluated, revealing prevalence 37.8%. Logistic regression analysis highlighted age ≥ 45 years (odds ratio [OR] 2.44, 95% confidence interval [CI] 1.50–3.99, < 0.001) body mass index (BMI) 24.0 kg/m2 (OR 2.12, CI 1.27–3.54, 0.004) independent TBI. do appear reactivate TBI, potentially reducing need screening treatment. Chinese Clinical Trial Registry, ChiCTR2100045823.